Codiak BioSciences Revenue and Competitors
Estimated Revenue & Valuation
- Codiak BioSciences's estimated annual revenue is currently $20.5M per year.
- Codiak BioSciences received $76.5M in venture funding in November 2017.
- Codiak BioSciences's estimated revenue per employee is $155,000
- Codiak BioSciences's total funding is $234.9M.
- Codiak BioSciences has 132 Employees.
- Codiak BioSciences grew their employee count by -2% last year.
Codiak BioSciences Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Codiak BioSciences?
Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth. Recent discoveries have transformed our understanding of the role of exosomes in the body. We now know that these natural, cell-derived vesicles can act as a potent and safe delivery system for multiple therapeutic payloads. Recognizing the enormous potential of exosomes, Codiak is applying leading-edge translational science and rigorous drug development to build a pipeline of candidates with broad utility and the capacity to address currently undruggable targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas. At Codiak, we are working to create a major shift in the development of tomorrow's medicines through scientific ambition, remarkable ingenuity and deep passion for improving patients lives. Located in the heart of Boston's biotechnology hub in Cambridge, Massachusetts, we are advancing a bold vision by tapping into the unique talents of a varied pool of individuals who together are achieving truly exceptional work. Come Join Us.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Codiak BioSciences News
HOUSTON — It was a banner achievement for MD Anderson Cancer Center. Top biotech investors had licensed some of its research to launch a high-profile cancer diagnostic and therapeutics company, backed by more than $80 million. As Codiak BioSciences was being formed in 2015, though, Ferran Prat, ...
It’s had big names join its ranks and big backing from VCs; now, early-stage exosome biotech Codiak BioSciences wants in on the public market. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scientist for an entire year? Enter the Agilent Lab ...
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the pricing of its underwritten publ ...
Codiak BioSciences, Evox Therapeutics Ltd., Exosome Diagnostics Inc., HansaBioMed Life Sciences Ltd. (Lonza), NonoSomiX Inc., and ...
Takara Bio Company, Illumina Inc, Thermo Fisher Scientific Inc, Codiak BioSciences, Evox Therapeutics Limited, HansaBioMed Life Sciences, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Codiak BioSciences Inc., a company pioneering exosomes as a new class of biologic medicines, ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Codiak BioSciences Funding
|2015-11-18||$80.0M||Undisclosed||ARCH Venture Partners||Article|
|2016-01-27||$61.0M||B||ARCH Venture Partners||Article|